Inventiva S.A.(IVA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

IVA Inventiva S.A.

Trading 09-15 15:31:19 EDT

3.84

-0.04

-1.16%

High4.03	Low3.72	Vol2.07M
Open3.90	D1 Closing3.88	Amplitude7.86%
Mkt Cap905.06M	Tradable Cap690.30M	Total Shares236.00M
T/O8.05M	T/O Rate1.15%	Tradable Shares180.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"IVA","market":"US","secType":"STK","nameCN":"Inventiva S.A.","latestPrice":3.835,"timestamp":1789500675003,"preClose":3.88,"halted":0,"volume":2065193,"delay":0,"changeRate":-0.011597938144329878,"floatShares":180000000,"shares":236000000,"eps":-2.230832,"marketStatus":"Trading","change":-0.045,"latestTime":"09-15 15:31:19 EDT","open":3.9,"high":4.025,"low":3.72,"amount":8052911.1506272,"amplitude":0.078608,"askPrice":3.84,"askSize":806,"bidPrice":3.83,"bidSize":604,"shortable":3,"etf":0,"ttmEps":-2.230832,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1789502400000},"marketStatusCode":2,"adr":0,"adrRate":1,"listingDate":1594353600000,"exchange":"NASDAQ","adjPreClose":3.88,"preHourTrading":{"tag":"盘前","latestPrice":3.93,"preClose":3.88,"latestTime":"09:28 EDT","volume":7514,"amount":29393.5154162,"timestamp":1789478880061,"change":0.05,"changeRate":0.012887,"amplitude":0.03866},"postHourTrading":{"tag":"盘后","latestPrice":3.88,"preClose":3.88,"latestTime":"17:38 EDT","volume":3782,"amount":14674.16,"timestamp":1789421898615,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.505933,"impliedVol":2.3896,"impliedVolPercentile":0.6226},"requestUrl":"/m/hq/s/IVA/wiki","defaultTab":"wiki","newsList":[{"id":"2667964295","title":"Analysts Have Conflicting Sentiments on These Healthcare Companies: SanBio Co (OtherSNBIF), Immutep Ltd (OtherPRRUF) and Inventiva (IVA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2667964295","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667964295?lang=en_us&edition=fundamental","pubTime":"2026-09-15 20:20","pubTimestamp":1789474816,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on SanBio Co (SNBIF), Immutep Ltd (PRRUF) and Inventi...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-sanbio-co-othersnbif-immutep-ltd-otherprruf-and-inventiva-iva-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-sanbio-co-othersnbif-immutep-ltd-otherprruf-and-inventiva-iva-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HCSG","XLV","XBI","SNBIF","BK4581","BK4585","LABU","BK4137","LU0128526141.USD","BK4588","BK4139","PRRUF","LU0029874061.USD","IVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667918642","title":"Inventiva price target raised to $14 from $11 at Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2667918642","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667918642?lang=en_us&edition=fundamental","pubTime":"2026-09-15 20:15","pubTimestamp":1789474523,"startTime":"0","endTime":"0","summary":"Guggenheim analyst Seamus Fernandez raised the firm’s price target on Inventiva (IVA) to $14 from $11 and keeps a Buy rating on the shares ahead of...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/inventiva-price-target-raised-to-14-from-11-at-guggenheim-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/inventiva-price-target-raised-to-14-from-11-at-guggenheim-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IVA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667064432","title":"Guggenheim Sticks to Its Buy Rating for Inventiva (IVA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2667064432","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667064432?lang=en_us&edition=fundamental","pubTime":"2026-09-15 19:35","pubTimestamp":1789472141,"startTime":"0","endTime":"0","summary":"Guggenheim analyst Seamus Fernandez maintained a Buy rating on Inventiva today and set a price target of $14.00. According to TipRanks, Fernandez i...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/guggenheim-sticks-to-its-buy-rating-for-inventiva-iva-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/guggenheim-sticks-to-its-buy-rating-for-inventiva-iva-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664445528","title":"Inventiva Says All Patients Completed 72-Week Treatment Period in Phase 3 Liver Disease Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2664445528","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664445528?lang=en_us&edition=fundamental","pubTime":"2026-09-03 05:44","pubTimestamp":1788385469,"startTime":"0","endTime":"0","summary":"Inventiva  said late Wednesday that last patient completed the final 72-week visit in its NATiV3 phase 3 trial evaluating lanifibranor for patients with metabolic dysfunction-associated steatohepatitis, a common and progressive chronic liver disease, with moderate to advanced fibrosis.All patients have completed the 72-week treatment period, according to a statement.The study enrolled 1,009 patients in the main cohort and 410 patients in the exploratory cohort, the company said.Inventiva said it expects to report topline results in Q4, and plans to seek regulatory approval in H1 of 2027, if results are favorable.Also, the company updated timing of its H1 financial results to Sept. 28, revised from the prior date of Sept. 25.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","IVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664841533","title":"Inventiva announces last patient visit in NATiV3 trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2664841533","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664841533?lang=en_us&edition=fundamental","pubTime":"2026-09-03 04:35","pubTimestamp":1788381316,"startTime":"0","endTime":"0","summary":"Inventiva (IVA) announced the last patient has completed their final 72-week visit in the NATiV3 Phase 3 clinical trial evaluating lanifibranor for...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/inventiva-announces-last-patient-visit-in-nativ3-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/inventiva-announces-last-patient-visit-in-nativ3-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NVIB","GDOC","MEDX","BK4139","IVA","HYLG","IDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664883867","title":"Inventiva Names Chris Benecchi COO","url":"https://stock-news.laohu8.com/highlight/detail?id=2664883867","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664883867?lang=en_us&edition=fundamental","pubTime":"2026-09-01 04:20","pubTimestamp":1788207632,"startTime":"0","endTime":"0","summary":"Inventiva (IVA) said late Monday it appointed Chris Benecchi as chief operating officer.Benecchi was most recently the chief executive officer of Motric Bio, the biopharmaceutical company said.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["COO","GB00BDT5M118.USD","BK4139","BK4198","LU2272731600.USD","BK4585","LU1992135472.HKD","LU2272731782.SGD","IVA","LU1992135399.USD","LU2211815571.USD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664883852","title":"Inventiva appoints Chris Benecchi as COO","url":"https://stock-news.laohu8.com/highlight/detail?id=2664883852","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664883852?lang=en_us&edition=fundamental","pubTime":"2026-09-01 04:15","pubTimestamp":1788207329,"startTime":"0","endTime":"0","summary":"Inventiva (IVA) announced the appointment of Chris Benecchi as COO. Benecchi will lead Inventiva’s operational readiness as the company approaches ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/inventiva-appoints-chris-benecchi-as-coo-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/inventiva-appoints-chris-benecchi-as-coo-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4198","BK4588","IVA","LU2272731782.SGD","LU1992135399.USD","BK4139","BK4585","LU1992135472.HKD","COO","LU2272731600.USD","GB00BDT5M118.USD","LU2211815571.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654571017","title":"Wall Street Analysts Are Bullish on Top Healthcare Picks","url":"https://stock-news.laohu8.com/highlight/detail?id=2654571017","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654571017?lang=en_us&edition=fundamental","pubTime":"2026-07-27 19:50","pubTimestamp":1785153023,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on HCA Healthcare (HCA), Inventiva (IVA) and MannKind (...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/wall-street-analysts-are-bullish-on-top-healthcare-picks-blurbs-news-263?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/wall-street-analysts-are-bullish-on-top-healthcare-picks-blurbs-news-263?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1119994496.HKD","LU1201861249.SGD","LU0128525929.USD","LU0029864427.USD","BK4185","LU0114720955.EUR","LU0187121727.USD","SG9999014039.USD","LU0310800379.SGD","LU0868494617.USD","IE00B3S45H60.SGD","LU0985489474.SGD","LU0878866978.SGD","LU1150488218.USD","LU1084165304.USD","SG9999014013.SGD","HCA","SG9999014021.USD","IVA","IHF","LU0708994859.HKD","IE00B775SV38.USD","LU0068578508.USD","BK4504","SG9999014005.SGD","LU0130102774.USD","LU1489326972.SGD","LU0211327993.USD","BK4588","BK4139","LU0980610538.SGD","LU0203345920.USD","LU0882574055.USD","LU1267930573.SGD","LU1150488135.SGD","BK4585","LU0310799852.SGD","LU0648001328.SGD","LU2355687059.USD","LU0433182093.SGD","LU1261432733.SGD","LU1267930490.SGD","LU0203347892.USD","LU0211328371.USD","LU2244417387.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652169288","title":"Inventiva Initiated at Overweight by Cantor Fitzgerald","url":"https://stock-news.laohu8.com/highlight/detail?id=2652169288","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652169288?lang=en_us&edition=fundamental","pubTime":"2026-07-17 20:09","pubTimestamp":1784290140,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/IVA/analyst-ratings(END) Dow Jones NewswiresJuly 17, 2026 08:09 ET","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650136711","title":"European Equities Traded in the US as American Depositary Receipts Decline Friday","url":"https://stock-news.laohu8.com/highlight/detail?id=2650136711","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650136711?lang=en_us&edition=fundamental","pubTime":"2026-07-10 23:11","pubTimestamp":1783696303,"startTime":"0","endTime":"0","summary":"European equities traded in the US as American depositary receipts were lower on Friday morning, shedding 0.2% to 1,899.89 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by steel producer ArcelorMittal  and bank BBVA , which rose 5.2% and 1.4% respectively.They were followed by technology company Opera , which added 0.9%.The decliners from continental Europe were led by clinical-stage biopharmaceutical company Inventiva  and technology company Nokia , which fell 5.6% and 4.2% respectively.They were followed by pharmaceutical company Argenx , which shed 3.6%.From the UK and Ireland, the gainers were led by telecom giant Vodafone  and advertising agency WPP , which rose 13% and 4.9% respectively.The decliners from the UK and Ireland were led by pharmaceutical company Silence Therapeutics  and biotech company Autolus Therapeutics , which lost 7% and 6.8% respectively.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4023","IE00BMPRXR70.SGD","IEUR","VOD","WPP.AU","ARGX","IE0009355771.USD","IE0034235188.USD","BK4107","AFG","BK4006","EPV","FMED","IE00B4R5TH58.HKD","BK4561","LU0320765992.SGD","BK4020","IE00B2B36J28.USD","LU2324357040.USD","LU0006061336.USD","BBVA","LU1983260115.SGD","BK4585","NOK","LU0889565916.HKD","BK4117","BK4207","BK4532","IE00BJT1NW94.SGD","SLN","BK4588","LFGY","BK4132","IVA","LU0109394709.USD","BK4139","BK4009","IE00BMPRXN33.USD","WPP","IBB","LNOK","MT","IE0002141913.USD","IE00BJJMRZ35.SGD","OPRA","BK4505","BK4547","AUTL","IE00BFTCPJ56.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650780109","title":"European Equities Traded in the US as American Depositary Receipts Rise Thursday","url":"https://stock-news.laohu8.com/highlight/detail?id=2650780109","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650780109?lang=en_us&edition=fundamental","pubTime":"2026-07-09 23:10","pubTimestamp":1783609858,"startTime":"0","endTime":"0","summary":"European equities traded in the US as American depositary receipts were rising on Thursday morning, up 0.5% to 1,905.06 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by technology giants Nokia  and Ericsson , which gained 6% and 4.4% respectively. They were followed by semiconductor company STMicroelectronics , which climbed nearly 4%.The decliners from continental Europe were led by clinical-stage biopharmaceutical company Inventiva  and steel producer ArcelorMittal , which fell 4.3% and 1.5% respectively. They were followed by software company SAP , which shed 0.7%.From the UK and Ireland, the gainers were led by semiconductor company Arm  and bank HSBC , which climbed 12% and 2% respectively. They were followed by bank Barclays , which added 1.8%.The decliners from the UK and Ireland were led by pharmaceutical company Compass Pathways  and budget airline Ryanair , which decreased 2.2% and 1.5% respectively.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4543","BK4528","BCS","BK4207","BK4554","LU2543165471.USD","LU0052756011.USD","LU1232071149.USD","IE00BMPRXR70.SGD","QQQA","BK4566","SPRX","STM","LU1267930227.SGD","BK4500","LU0310800965.SGD","PSIL","LU0496365809.HKD","BK4609","LU0348723411.USD","BK4023","LU0976567544.SGD","BK4139","LU0211326755.USD","BK4141","BK4548","SAP","LU0128525689.USD","BK4532","LU2236285917.USD","LU0266013472.USD","RYAAY","00005","BK4515","BK4605","ARM","CMPS","ARMU","BK4521","BK4604","ERIC","BK4591","LU0648000940.SGD","TRFK","IVA","HSBC","BK4585","BK4613","MT","LU0130103400.USD","BK4547","LU1201861165.SGD","BK4561","ARMW","BK4008","IE00BMPRXN33.USD","BK4020","IE00BMPRXQ63.HKD","LU0081259029.USD","LU0211326839.USD","AIPI","HSBH","LU0006061336.USD","LNOK","ARMG","BK4006","BK4588","NOK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648638549","title":"Press Release: Results of the Votes of the Combined Shareholders' General Meeting of June 30, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2648638549","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648638549?lang=en_us&edition=fundamental","pubTime":"2026-07-03 04:00","pubTimestamp":1783022400,"startTime":"0","endTime":"0","summary":"-- Total number of shares with voting rights: 236 280 202. Present                  5     318 490     519 790             5     318 490     519 790. The Chairman           214  21 380 077  21 505 444           214  21 380 077  21 505 444. 148 125     155 342                   148 125     155 342","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IVA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643270086","title":"Analysts Offer Insights on Healthcare Companies: Inventiva (IVA), Rhythm Pharmaceuticals (RYTM) and Belite Bio, Inc. ADR (BLTE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2643270086","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643270086?lang=en_us&edition=fundamental","pubTime":"2026-06-15 19:10","pubTimestamp":1781521813,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Inventiva (IVA), Rhythm Pharmaceuticals (RYTM) and B...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-inventiva-iva-rhythm-pharmaceuticals-rytm-and-belite-bio-inc-adr-blte-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-inventiva-iva-rhythm-pharmaceuticals-rytm-and-belite-bio-inc-adr-blte-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","BLTE","LU0029874061.USD","XLV","BK4588","XBI","BK4581","HCSG","LU0128526141.USD","IVA","BK4007","BK4137","RYTM","LABU","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642924004","title":"Press Release: Statement of Total Voting Rights and Shares Forming The Company's Share Capital as of May 22, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2642924004","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642924004?lang=en_us&edition=fundamental","pubTime":"2026-06-10 04:00","pubTimestamp":1781035200,"startTime":"0","endTime":"0","summary":"Number of Shares    Total Voting Rights,  Total Voting Rights,May 22, 2026           209 007 475           218 082 368           218 082 368. basis for calculating threshold crossings. In accordance with Article. 223-11 of the AMF General Regulations, this number is calculated on the. basis of all shares to which voting rights are attached, including those. voting rights is calculated without taking into account shares for which. voting rights have been suspended, i.e. treasury shares (including shares. purchased under the liquidity contract). It is released in order to. Inventiva is a clinical-stage biopharmaceutical company focused on the research and development of an orally administered small molecule for the treatment of patients with MASH. The Company is currently evaluating lanifibranor, a novel pan-PPAR agonist, in the NATiV3 pivotal Phase 3 clinical trial for the treatment of adult patients with MASH, a common and progressive chronic liver disease.Media Relations Pascaline Cle","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IVA","TSS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642401492","title":"Press Release: Combined General Meeting of June 30, 2026 - Availability of the Preparatory Documents","url":"https://stock-news.laohu8.com/highlight/detail?id=2642401492","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642401492?lang=en_us&edition=fundamental","pubTime":"2026-06-10 04:00","pubTimestamp":1781035200,"startTime":"0","endTime":"0","summary":"Daix , New York City , June 9,2026 -- Inventiva  , a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis , today announced the availability of the preparatory documents for the Combined General Meeting of June 30, 2026.Shareholders are invited to participate in the Combined General Meeting that will be held on June 30, 2026 at 2 p.m. at Htel Villa M, 24 -- 30 Boulevard Pasteur, 75015 Paris .In accordance with Articles R. 225-83 and R. 225-89 of the French Commercial Code, documents that must be available for the shareholders for the","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641748978","title":"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Apogee Therapeutics (APGE), Inventiva (IVA) and Roche Holding AG (OtherRHHVF)","url":"https://stock-news.laohu8.com/highlight/detail?id=2641748978","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641748978?lang=en_us&edition=fundamental","pubTime":"2026-06-08 19:40","pubTimestamp":1780918856,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Apogee Therapeutics (APGE), Inventiva (IVA) and Ro...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-apogee-therapeutics-apge-inventiva-iva-and-roche-holding-ag-otherrhhvf-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-apogee-therapeutics-apge-inventiva-iva-and-roche-holding-ag-otherrhhvf-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","HCSG","BK4210","LU0128526141.USD","LU0029874061.USD","LABU","XLV","IVA","AG","BK4137","LU0053671581.USD","BK4585","BK4581","BK4139","XBI","APGE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640687153","title":"Inventiva (IVA) Receives a Buy from Barclays","url":"https://stock-news.laohu8.com/highlight/detail?id=2640687153","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640687153?lang=en_us&edition=fundamental","pubTime":"2026-06-04 16:36","pubTimestamp":1780562196,"startTime":"0","endTime":"0","summary":"Barclays analyst Eliana Merle maintained a Buy rating on Inventiva today and set a price target of $18.00. Merle covers the Healthcare sector, focu...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/inventiva-iva-receives-a-buy-from-barclays-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/inventiva-iva-receives-a-buy-from-barclays-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IVA","XBI","XLV","BK4139","BK4581","LABU","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640582912","title":"Inventiva files automatic mixed securities shelf","url":"https://stock-news.laohu8.com/highlight/detail?id=2640582912","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640582912?lang=en_us&edition=fundamental","pubTime":"2026-06-02 18:26","pubTimestamp":1780396000,"startTime":"0","endTime":"0","summary":"06:12 EDT Inventiva (IVA) files automatic mixed securities shelf Published first on TheFly – the ultimate source for real-time, market-moving break...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/inventiva-files-automatic-mixed-securities-shelf-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/inventiva-files-automatic-mixed-securities-shelf-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","IVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633021579","title":"eGain Launches AI Agent IVA to Deliver Accurate, Conversational Customer Service","url":"https://stock-news.laohu8.com/highlight/detail?id=2633021579","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633021579?lang=en_us&edition=fundamental","pubTime":"2026-05-06 15:56","pubTimestamp":1778054160,"startTime":"0","endTime":"0","summary":"Intelligent Virtual Agent brings trusted knowledge to every customer conversationSUNYVALE, Calif., May  06, 2026 (GLOBE NEWSWIRE) -- eGain (NASDAQ: EGAN) today announced the launch of AI Agent IVA, an","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/06/3288531/0/en/eGain-Launches-AI-Agent-IVA-to-Deliver-Accurate-Conversational-Customer-Service.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4587","BK4528","BK4543","BK4588","CHAT","EGAN","AIYY","BK4023","BK4139","BK4551","AIPO","ARTY","BK4585","IVA","AGIX","AI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629079968","title":"Inventiva Names Malkomes as CFO Ahead of Lanifibranor Phase 3 Readout","url":"https://stock-news.laohu8.com/highlight/detail?id=2629079968","media":"Dow Jones","labels":["executive","dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629079968?lang=en_us&edition=fundamental","pubTime":"2026-04-23 06:51","pubTimestamp":1776898260,"startTime":"0","endTime":"0","summary":"Inventiva appointed Axel-Sven Malkomes as its new chief financial officer ahead of the company's planned readout of Phase 3 trial results for lanifibranor, a liver-disease treatment.Current Chief Financial Officer Jean Volatier will stay on as the biopharmaceutical company's executive vice president, finance & corporate social responsibility.Malkomes most recently served as CFO of CureVac. He has also served as CFO of Cardio, helping lead its acquisition by Novo Nordisk, as well as CFO and chief business officer at Midigene.The company also named Susan Coles as its chief legal officer and Pamela Herbster as its chief people officer.Coles was previously head of legal and finance for Vivet Therapeutics. She also served two stints as Inventiva's general counsel, from 2012 to 2014 and from 2019 to 2021.Herbster previously led human resources and business operations at Sage Therapeutics.They are joining Inventiva in advance of its readout of trial results for lanifibranor, a treatment for m","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Inventiva Names Malkomes as CFO Ahead of Lanifibranor Phase 3 Readout","news_tag":"executive,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IVA"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.inventivapharma.com","stockEarnings":[{"period":"1week","weight":-0.1883},{"period":"1month","weight":-0.1565},{"period":"3month","weight":0.0838},{"period":"6month","weight":-0.349},{"period":"1year","weight":-0.3084},{"period":"ytd","weight":-0.1656}],"compareEarnings":[{"period":"1week","weight":-0.0121},{"period":"1month","weight":-0.0199},{"period":"3month","weight":0.0141},{"period":"6month","weight":0.1504},{"period":"1year","weight":0.1574},{"period":"ytd","weight":0.1158}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of mucopolysaccharidoses type VI disease. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company was founded in 2011 and is headquartered in Daix, France.","yearOnYearQuotes":[{"month":1,"riseRate":0.666667,"avgChangeRate":0.098872},{"month":2,"riseRate":0.666667,"avgChangeRate":0.043927},{"month":3,"riseRate":0,"avgChangeRate":-0.112386},{"month":4,"riseRate":0.166667,"avgChangeRate":-0.080671},{"month":5,"riseRate":0.5,"avgChangeRate":0.083353},{"month":6,"riseRate":0.166667,"avgChangeRate":-0.137783},{"month":7,"riseRate":0.5,"avgChangeRate":-0.026084},{"month":8,"riseRate":0.428571,"avgChangeRate":0.134717},{"month":9,"riseRate":0.285714,"avgChangeRate":-0.055706},{"month":10,"riseRate":0.666667,"avgChangeRate":0.071747},{"month":11,"riseRate":0.166667,"avgChangeRate":-0.025201},{"month":12,"riseRate":0.833333,"avgChangeRate":0.034174}],"exchange":"NASDAQ","name":"Inventiva S.A.","nameEN":"Inventiva S.A.","securityTypeName":"DR","adrRate":"1:1"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.0","shortVersion":"4.50.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Inventiva S.A.(IVA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Inventiva S.A.(IVA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Inventiva S.A.,IVA,Inventiva S.A.股票,Inventiva S.A.股票老虎,Inventiva S.A.股票老虎国际,Inventiva S.A.行情,Inventiva S.A.股票行情,Inventiva S.A.股价,Inventiva S.A.股市,Inventiva S.A.股票价格,Inventiva S.A.股票交易,Inventiva S.A.股票购买,Inventiva S.A.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Inventiva S.A.(IVA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Inventiva S.A.(IVA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction